Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/25/2010WO2010133574A1 Opioid receptors stimulating compounds (thymoquinone, nigella sativa) and food allergy
11/25/2010WO2010133569A1 Azabicyclo[4.1.0]heptane derivatives
11/25/2010WO2010133544A1 Piperazine and aminopyrrolidine compounds as histamine h3 receptor antagonists
11/25/2010WO2010133534A1 Bicyclic amino substituted compounds as pi3k inhibitors
11/25/2010WO2010133528A1 Heterocyclic antiviral compounds
11/25/2010WO2010133457A1 Salts of tiotropium with 10-camphorsulfonic acid
11/25/2010WO2010133377A1 Fat blends and uses thereof
11/25/2010WO2010133359A2 The improvement of gastrointestinal health, immunity and performance by dietary intervention
11/25/2010WO2010133314A1 Medication for oral administration, comprising at least one estrogen and/or at least one gestagen and at least one probiotic bacterial strain
11/25/2010WO2010133312A1 Halogen-substituted compounds as pesticides
11/25/2010WO2010133166A1 Use of paederosidic acid for preparing analgesic and/or anti-inflammatory medicaments
11/25/2010WO2010133016A1 Pharmaceutical composition for treating depression, preparation method and use therefor
11/25/2010WO2010133015A1 Pharmaceutical composition for treating depression and preparative method and use thereof
11/25/2010WO2010132999A1 Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
11/25/2010WO2010132992A1 Compounds for the inhibition of herpesviruses
11/25/2010WO2010132982A1 Treatment of muscle disease characterized by insulin resistance
11/25/2010WO2010132959A1 Use of dynamin ring stabilizers
11/25/2010WO2010116380A3 A one pot process for preparing 2-butyl-3-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro [4, 4] non-1-en-4-one (irbesartan)
11/25/2010WO2010114928A3 Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
11/25/2010WO2010114215A3 Composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising camphor as an active ingredient
11/25/2010WO2010112842A3 Anti viral therapy
11/25/2010WO2010111471A3 RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/25/2010WO2010109482A3 Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions
11/25/2010WO2010109334A3 Thienopyrimidinedione derivatives as trpa1 modulators
11/25/2010WO2010106436A3 Novel anti-inflammatory agents
11/25/2010WO2010105008A3 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
11/25/2010WO2010104485A3 Valsartan formulations
11/25/2010WO2010103545A8 Method of use of vitamin k as energy enhancer in diverse disease states
11/25/2010WO2010100650A3 Therapeutic uses of mastic gum fractions
11/25/2010WO2010099379A8 Jak kinase modulating quinazoline derivatives and methods of use thereof
11/25/2010WO2010093615A3 Compounds, their syntheses, compositions, and methods to treat cancer
11/25/2010WO2010093523A3 Foamable microemulsion compositions for topical administration
11/25/2010WO2010093452A3 Reducible polymers for non-viral gene delivery
11/25/2010WO2010092590A3 Process for the preparation of doxorubicin liposomes
11/25/2010WO2010092485A3 Combined treatment of multiple sclerosis
11/25/2010WO2010090765A3 Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
11/25/2010WO2010089760A3 Controlled release, multiple unit pharmaceutical compositions
11/25/2010WO2010088375A3 Method of synergistically enhancing the therapeutic efficacy and safety of medications through a combination therapy
11/25/2010WO2010088050A3 Bicyclic pyrazolo-heterocycles
11/25/2010WO2010085820A3 Tricyclic compounds as antagonists of prostaglandin d2 receptors
11/25/2010WO2010085128A3 Processes for preparing hiv reverse transcriptase inhibitors
11/25/2010WO2010083237A3 Composition and methods to manage the inflammatory basis of chronic disease conditions and maintain an optimal immune response in elderly
11/25/2010WO2010082785A3 Oral pharmaceutical composition
11/25/2010WO2010081082A3 Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
11/25/2010WO2010081079A3 Composition and method for treatment of diabetes
11/25/2010WO2010080817A3 Carbohydrate-cyclopamine conjugates as anticancer agents
11/25/2010WO2010080730A3 Methods and materials for delivering bile acids
11/25/2010WO2010080415A3 Substituted afpo (6-aryl-4h-furo[3,2-c]pyran-4-one) derivatives as anti-cancer agents
11/25/2010WO2010076731A3 Vitamin d promoting sunscreen
11/25/2010WO2010072398A3 Pharmaceutical formulations comprising buprenorphine and an alcohol
11/25/2010WO2010071872A3 [2.2.2] bicyclic derivatives and methods of use
11/25/2010WO2010065756A3 Usirna complexes
11/25/2010WO2010064248A3 Methods of diagnosing and treating motor neuron diseases
11/25/2010WO2010063995A3 Telmisartan with diuretic formulations
11/25/2010WO2010057020A3 Modification of amyloid-beta load in non-brain tissue
11/25/2010WO2010056585A3 Heteroaryl diamide compounds useful as mmp-13 inhibitors
11/25/2010WO2010051129A3 New imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use
11/25/2010WO2010049449A3 Novel salts of sunitinib
11/25/2010WO2010048087A3 Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
11/25/2010WO2010047803A3 A method for the treatment of proliferative disorders of the eye
11/25/2010WO2010033509A3 14-hydroxy-docosahexaenoic acid compounds
11/25/2010WO2010027448A8 Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists
11/25/2010WO2010025491A9 Treatment of neonate foals with meloxicam
11/25/2010WO2010018408A3 Pharmaceutical compositions with tetrabenazine
11/25/2010WO2010003533A3 Pyridopyrimidine compounds as anti-tubercular agents
11/25/2010WO2009148580A3 Controlled release copolymer formulation with improved release kinetics
11/25/2010WO2009137871A8 Methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells
11/25/2010WO2009132202A3 Macrocyclic compounds and their use as kinase inhibitors
11/25/2010WO2009121042A8 Quinazoline derivatives and methods of treatment
11/25/2010WO2009111820A9 Modalmetric fibre sensor
11/25/2010WO2009078040A3 Compounds inducing reperfusion in ischaemic tissues
11/25/2010WO2009078039A3 Compound inducing angiogenesis response in ischaemic tissues
11/25/2010WO2009052624A9 Inhalation compositions comprising montelukast acid and a pde-4 inhibitor or an inhaled corticosteroid
11/25/2010WO2009023030A8 Immediate release and sustained release ibuprofen dosing regimen
11/25/2010US20100299769 Novel peptide involved in energy homeostasis
11/25/2010US20100299768 Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease
11/25/2010US20100299767 Trem-2 gene and protein as inhibitors of expression of ga733-2, and transgenic animals comprising the same and uses thereof
11/25/2010US20100299766 Mouse models carrying a knock-out mutation of the qpctl-gene
11/25/2010US20100298762 Methods and Devices for Improved Efficiency of RNA Delivery to Cells
11/25/2010US20100298758 Method for non-therapeutic or therapeutic photodynamic skin treatment
11/25/2010US20100298735 Methods For Classifying And Treating Physiologic Brain Imbalances Using Quantitative EEG
11/25/2010US20100298628 Stress urinary incontinence treatment
11/25/2010US20100298525 Functionalized water-soluble polyphosphazenes and uses thereof as modifiers of biological agents
11/25/2010US20100298445 Optimized Fluorocarbon Emulsions for Blood Substitutes and Other Therapeutic Uses
11/25/2010US20100298444 Method for improving the therapeutic efficacy of curcuminoids and their analogs
11/25/2010US20100298443 Methods and compositions for treating ophthalmic conditions with retinyl derivatives
11/25/2010US20100298442 1-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
11/25/2010US20100298441 Titration package for neramexane and its use in the treatment of an inner ear disorder
11/25/2010US20100298440 1-aminocyclohexane derivatives for the treatment of hearing loss
11/25/2010US20100298439 Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors
11/25/2010US20100298438 Gene expression profiling of parkinson's disease
11/25/2010US20100298437 Use of citrulline for treating undernutrition conditions
11/25/2010US20100298436 EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists
11/25/2010US20100298435 Stable Emulsions of Oils in Aqueous Solutions and Methods for Producing Same
11/25/2010US20100298434 Neuroprotection and prevention of dopaminergic cell death by targeting nur77 translocation
11/25/2010US20100298433 Branched chain fatty acids for prevention or treatment of gastrointestinal disorders
11/25/2010US20100298432 Cosmetic Compositions Containing Esters of 2-Butyloctanol
11/25/2010US20100298431 Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease
11/25/2010US20100298430 Prophylactic antistress agent
11/25/2010US20100298429 stable liquid drug composition comprising carbidopa, and arginine for treating Parkinson's disease; additional including entacapone or tolcapone; long half life; transdermal delivery
1 ... 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 ... 7860